Tecan Group AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCGGY research report →
Price Chart
About the company
Tecan Group AG delivers advanced laboratory instruments and complete solutions to a diverse client base, including pharmaceutical and biotechnology companies, academic research institutions, and both forensic and diagnostic laboratories. The company operates through two primary segments: Life Sciences Business and Partnering Business. Its comprehensive product range features liquid handling and automation systems, microplate readers and washers, various consumables, next-generation sequencing (NGS) reagents, immunoassays, microbodies, and specialized software.
- CEO
- Monica Manotas
- IPO
- 2022
- Employees
- 3,244
- HQ
- Männedorf, ZH, CH
Get TickerSpark's AI analysis on TCGGY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.28B
- P/E
- -21.51
- PEG
- 0.08
- P/S
- 2.86
- P/B
- 2.18
- EV/EBITDA
- 26.34
- Div Yield
- 1.52%
- Gross Margin
- 34.06%
- Op Margin
- 4.60%
- Net Margin
- -13.36%
- ROE
- -10.25%
- ROIC
- 2.91%
Latest fiscal year · YoY change
- Revenue
- $882.48M-5.5%
- Gross Profit
- $310.84M-3.0%
- Op Income
- $24.11M
- Net Income
- $-110,653,000-263.5%
- EPS
- $-1.75-265.4%
- OCF Growth
- -7.1%
- FCF Growth
- -12.9%
- 52W High
- $38.38
- 52W Low
- $36.00
- 50D MA
- $36.00
- 200D MA
- $36.00
- Beta
- 1.08
- RSI (14)
- 33
- Avg Volume
- 13
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tecan delivered modest first-half sales growth and improved adjusted EBITDA margin, while emphasizing Rewired-driven savings, AI-related opportunities, and a cautious but unchanged full-year outlook.· August 11, 2026
- Group sales were CHF 427.5 million, up 3.4% in local currencies, with order entry of CHF 444.3 million and a book-to-bill ratio of 1.04.
- Adjusted EBITDA was CHF 64.5 million with a 15.1% margin, slightly ahead of last year, despite FX, tariffs, and transformation costs.
- Gross margin fell from 36.2% to 33.9% due mainly to material cost inflation, inventory valuation, FX, and tariffs.
- Operating cash flow was CHF 17 million, down sharply because of working capital, higher receivables, inventory buildup, and tax payments.
- Management kept full-year guidance unchanged: low single-digit sales growth in local currencies and a 15.5% to 16.5% adjusted EBITDA margin, with the margin expected toward the upper end.
- Rewired is starting to produce savings, but management said 2027 should see a larger cost and investment impact before benefits scale further in 2027-2028.
Tecan reported first-half 2026 sales of CHF 427.5 million, down 2.7% reported but up 3.4% in local currencies. Order entry was CHF 444.3 million, up 3.0% in local currencies, with a book-to-bill ratio of 1.04. Adjusted EBITDA was CHF 64.5 million, corresponding to a 15.1% margin, slightly above the 15.0% reported in H1 2025. Gross profit margin declined from 36.2% to 33.9%. Basic EPS was CHF 0.99 and adjusted EPS was CHF 2.62; reported net profit was CHF 12.3 million, and adjusted net profit was CHF 32.5 million, down 3.5%. Operating cash flow was CHF 17 million, and net liquidity over the last 12 months declined to CHF 73.5 million. For full-year 2026, management reiterated low single-digit sales growth in local currencies and adjusted EBITDA margin guidance of 15.5% to 16.5%, and said it now expects to finish toward the upper end of that range.
Monica Manotas framed H1 as a solid start to the Rewired transformation, saying the company is growing above market and seeing early benefits from actions already taken. She highlighted portfolio discipline, commercial excellence, and operational excellence as the three pillars of Rewired, with exits from non-core activities, AI-related partnerships, and supply-chain and manufacturing changes already underway. Her tone was confident but prudent: she said market recovery is still gradual and it is too early to declare a new trend, even though the company is seeing improvement in several end markets.
Camila Japur focused on the drivers behind margin and cash performance. She said gross margin fell to 33.9% from 36.2% mainly because of material inflation, inventory valuation, FX, and tariffs, while adjusted EBITDA margin still improved to 15.1% because of volume, mix, and the first Rewired benefits. She also quantified Rewired costs at CHF 7.6 million in H1, Elevate non-recurring costs at CHF 9.9 million, and noted the total Rewired OpEx is estimated at CHF 45 million to CHF 60 million. On cash, she said operating cash flow of CHF 17 million was hurt by receivables, inventory buildup, and tax payments, while dividend payments were CHF 37.2 million and treasury share purchases were CHF 30.5 million.
Analysts pressed management on whether Rewired savings are sustainable and whether the program could deliver upside; management said the early savings come from business exits and should be permanent, but that it is still early and the team is only one quarter into execution. Questions also focused on AI and the NVIDIA partnership; management said customer conversations are real, especially in clinical diagnostics and biopharma, but monetization is still at the beginning. On order momentum and H2 phasing, management said it feels good about the launch into the second half, but Partnering will face tougher comps and Cavro still has supply issues that should improve gradually through H2.
The call presented several positive drivers: above-market growth in both segments, a book-to-bill above 1, improving adjusted EBITDA margin, and early Rewired savings that management believes are sustainable. Management also described healthy demand in Biopharma, steady Diagnostics growth, improving instrumentation momentum, and meaningful interest from customers around AI-enabled automation and autonomous labs.
The main risks are that the market recovery is still gradual, Academia and Government remained weak, and management would not call a clear trend change yet. Gross margin and reported earnings were pressured by FX, tariffs, inventory, and transformation costs, while operating cash flow was notably weak and Cavro still faces supply challenges that will take time to unwind.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 19.8%
- Shares Outstanding
- 63.28M
- Float Shares
- 12.50M
Our TCGGY coverage
Recent articles, reports, and earnings notes.
No research on TCGGY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TCGGY report →Tecan Group AG (TCGGY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 11
Tecan Group AG (TCGGY) Analyst/Investor Day Transcript
seekingalpha.com · Mar 16
Tecan Group AG (TCGGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com · Jan 14
Tecan Group AG (TCHBF) Q2 2025 Earnings Call Transcript
seekingalpha.com · Aug 12
Tecan Group AG (TCHBF) Q4 2024 Earnings Call Transcript
seekingalpha.com · Mar 12
Tecan Group AG (TCHBF) Q2 2024 Earnings Call Transcript
seekingalpha.com · Aug 16
Tecan Group AG (TCHBF) Q4 2023 Earnings Call Transcript
seekingalpha.com · Mar 12
Tecan Group AG (TCHBF) Q2 2023 Earnings Call Transcript
seekingalpha.com · Aug 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.